Abstract Background The 7-valent and 13-valent pneumococcal conjugate vaccines (PCVs)
were introduced into the UK childhood immunization program in 2006 and 2010 …

It is unclear whether HIV-infected individuals remain at higher risk of invasive pneumococcal
disease (IPD) compared with HIV-uninfected individuals. We conducted a cohort study of …

Background The increasing use of highly active antiretroviral therapy (HAART) and
pneumococcal immunization along with shifting community exposures may have altered the …

Introduction Streptococcus pneumoniae is the commonest cause of bacteremic pneumonia
among HIV-infected persons. As more countries with high HIV prevalence are implementing …

Objectives: To examine invasive pneumococcal disease (IPD) incidence, the impact of the 7-
valent pneumococcal conjugate vaccines (PCV7s) programme on the distribution of …

Invasive pneumococcal diseases (IPDs) remain a significant cause of morbidity and
mortality in human immunodeficiency virus (HIV)-positive individuals despite the widespread …

Background: People with HIV (PWH) are at increased risk for invasive pneumococcal
disease (IPD). Thirteen-valent pneumococcal conjugate vaccine (PCV13) was …

Objective: Human immunodeficiency virus (HIV) infection and AIDS increase the risk of
invasive pneumococcal disease (IPD). We evaluated IPD among HIV-infected adults over a …

Background. Invasive pneumococcal disease (IPD) is an important cause of morbidity
among individuals infected with human immunodeficiency virus (HIV). We described …

Background Highly active antiretroviral treatment (HAART) programs have been associated
with declines in the burden of invasive pneumococcal disease (IPD) in industrialized …